BioMarin Pharma, Amgen, Sarepta Therapeutics, Chelsea Therapeutics Intl., and Theravance Early Briefing and Review

BioMarin Pharma, Amgen, Sarepta Therapeutics, Chelsea Therapeutics Intl., and
                     Theravance Early Briefing and Review

PR Newswire

LONDON, March 7, 2013

LONDON, March 7, 2013 /PRNewswire/ --

Markets inched up higher yesterday after hitting all time highs earlier this
week. The healthcare sector also showed promise as the the sector's stocks
moved up. The Dow Jones ended its latest session at 14,296.24, up 0.30 percent
while NASDAQ was down 0.05 percent to close at 3,222.37. Conversely, S&P also
ended on a positive note at 1,541.46, up 0.11 percent. Our research team took
a look at the biotech industry including major companies like BioMarin
Pharmaceutical Inc. (NASDAQ: BMRN), Amgen Inc. (NASDAQ: AMGN), Sarepta
Therapeutics Inc. (NASDAQ: SRPT), Chelsea Therapeutics International Ltd
(NASDAQ: CHTP) and Theravance Inc. (NASDAQ: THRX). StockCall has released free
charting and technical research on these aforementioned companies. Register to
read these reports at

http://www.stockcall.com/report 

BioMarin Pharmaceutical Inc. traded in the range of $60.30 and $61.64 in its
latest trading session and ended the day at $61.25, up 1.02 percent. The
stock's 52 weeks range stands at $31.91 and $61.64. BioMarin Pharma has gained
73.07 percent of its value in the past 12 months, while it gained 24.49
percent so far in 2013. The biotech company is in a bullish mode and may find
its first support level at $59.30. It is trading above its 20-day moving
average of $56.48. Sign up for the free report on BMRN at

http://www.StockCall.com/BMRN030713.pdf

Shares of Amgen Inc. ended yesterday's trading session marginally down at
$93.27 that is a drop of 0.18 percent, after creating a new 52 weeks high. The
stock gained more than 8 percent this year, in-line with the broad market. The
stock has slipped from $94.29 resistance level, which is also its new 52-week
high. It has support at around $92.36 at the moment. Despite its downward
move, Amgen is still trading above its 6-day and 20-day moving averages. AMGN
free technical report can be accessed by signing up at

http://www.StockCall.com/AMGN030713.pdf 

With a sharp upward movement in Wednesday's trading session, Sarepta
Therapeutics Inc. is up 21.36 percent for the year. It has gained 2,969
percent in the past 52 weeks. The stock closed 2.89 percent up at $31.31 on
volume of 1.73 million shares. Its average trading volume stands at 1.34
million shares. The company's shares currently face resistance at around
$31.52. The stock has support at around $28.14. It is currently trading above
its 20-day and 50-day moving averages, which is a bullish signal. Free report
on SRPT can be accessed by registering at

http://www.StockCall.com/SRPT 030713.pdf

Chelsea Therapeutics International Ltd traded in the range of $1.68 and $1.79
during yesterday's trading session. It opened at $1.69 and closed at $1.77, up
2.91 percent. The stock is currently in a bullish mode and has its first
resistance level at $1.87. Upon breaching this level, the biotech company may
go as high as $1.87. It traded 976,000 shares and is in-line with its 50-day
moving average price. Its first support level is at $1.48. In 2013, the stock
is up 132.89 percent so far. Register with StockCall and download the research
on CHTP for free at

http://www.StockCall.com/CHTX030713.pdf 

Despite the upward move shown by broad market indices, Theravance Inc.'s stock
finished 1.62 percent lower at $24.29, with volume down from daily average of
1.25 million to 944,000. The company's stock is up in 2013 so far with its
year-to-date gain at 9.22 percent. However, the stock currently shows a
neutral trend which is further confirmed by the stock's MACD chart. Theravance
has its first support level at $23.48. Read the full free research on THRX by
signing up to StockCall at

http://www.StockCall.com/THRX030713.pdf 

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at

http://www.stockcall.com 

SOURCE StockCall.com

Contact: Contact Person:William T. Knight, Email: info@stockcall.com, Contact
Number: +1(646)396-9857 (9:00 am EST - 01:30 pm EST)